Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 3, 2004-09 ,pp. : 211-213

Informa Healthcare

Access to resources Recommend Favorite

E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide

By Han Sehwan  

Breast Cancer Research and Treatment, Vol. 82, Iss. 1, 2003-01 ,pp. : 11-16

Springer Publishing Company

Access to resources Recommend Favorite

Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells

By Kurebayashi Junichi   Nukatsuka Mamoru   Nagase Hideki   Nomura Tsunehisa   Hirono Mai   Yamamoto Yutaka   Sugimoto Yoshikazu   Oka Toshinori   Sonoo Hiroshi  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 515-525

Springer Publishing Company

Access to resources Recommend Favorite

A let-7b binding site SNP in the 3'-UTR of the Bcl-xL gene enhances resistance to 5-fluorouracil and doxorubicin in breast cancer cells

By                

Oncology Letters, Vol. 9, Iss. 4, 2015-01 ,pp. : 1907-1911

Spandidos Publications

Access to resources Recommend Favorite

Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer-a randomised study with more than 10 years follow-up from the danish breast cancer cooperative gr

By Andersson M.   Lindegaard Madsen E.   Overgaard M.   Rose C.   Dombernowsky P.   Mouridsen H.T.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 39-46

Elsevier

Access to resources Recommend Favorite